SPI Pharma™

SPI Pharma, a leading supplier in the pharmaceutical formulation sector, is dedicated to overcoming the challenges of developing patient-friendly, effective, reliable, and safe dosage forms. By partnering with SPI Pharma, customers gain access to innovative solutions engineered to address formulation issues, differentiate products, and accelerate market entry. With a focus on the pharmaceutical market, SPI Pharma offers a range of products including antacid actives, excipients, and taste-masking technologies, serving over 55 countries with formulation innovation and technical support. Their commitment to quality is evident in their best-in-class products that meet global regulatory standards. Additionally, SPI Pharma's comprehensive Pharmasolutions program offers drug development and testing services to enhance drug portfolios.

Mannogem® Mannitol

More flexibility for formulators with lower total production costs!

Mannitol is a popular excipient used by drug manufacturers due to its unique, advantageous properties. It is inert, non-hygroscopic, and has high drug loading capabilities. Mannitol is also preferred for patients because it has a higher tolerance than alternatives such as lactose and fructose and mannitol has no impact on blood glucose levels, making it especially suitable for diabetic patients. SPI Pharma is the expert on mannitol and has recently increased their product offering with the addition of new Mannogem® grades to offer drug manufacturers even more options.

Mannogem® XL Technology improves compressibility and adds functionality

Mannogem® XL Technology combines SPI Pharma’s mannitol expertise with proprietary processing and advanced particle engineering. The result is compendial mannitol with a ground-breaking improvement in tableting. The superior functionality against standard grades of directly compressible (DC) mannitol (including increased tensile strength and improved friability) opens up new formulation possibilities – it works well with taste-masked APIs and enables advanced dosage forms like multiple unit particle systems (MUPS). XL Technology brings additional value to drug manufacturers by improving production with broader design space, higher yields, and faster production speeds. Mannitol produced with XL Technology also enhances the patient experience with better organoleptics to increase patient adherence.